Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins

doi:10.1084/jem.173.1.273

This Article

	Full Text (PDF, 381K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Jung, S.
	Articles by Schluesener, H. J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Jung, S.
	Articles by Schluesener, H. J.


Social Bookmarking

	What's this?

ARTICLES

Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins

S Jung and HJ Schluesener
Department of Neurology, University of Wurzburg, Federal Republic of Germany.

P21ras proteins are thought to play an important role in cell proliferation and differentiation. Single nucleotide mutations in the encoding cellular proto-oncogenes often result in p21ras proteins with transforming activity. Such activated ras oncogenes have been demonstrated in a variety of human malignancies and also in preneoplastic changes. Using a synthetic peptide corresponding to amino acids 5-16 of mutated p21ras proteins with an exchange of the normal glycine at position 12 by valine, it is shown here that human CD4+ T cells specifically recognize the mutated protein sequence and can be generated as antigen-specific T lymphocyte lines. The fact that these T lines did not crossreact to the sequence of normal p21ras proteins offers new perspectives for specific immunotherapy of human malignancies and even precancerous lesions.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Kubuschok, B., Neumann, F., Breit, R., Sester, M., Schormann, C., Wagner, C., Sester, U., Hartmann, F., Wagner, M., Remberger, K., Schilling, M., Pfreundschuh, M. (2006). Naturally Occurring T-Cell Response against Mutated p21 Ras Oncoprotein in Pancreatic Cancer. Clin. Cancer Res. 12: 1365-1372 [Abstract] [Full Text]
Francini, G., Scardino, A., Kosmatopoulos, K., Lemonnier, F. A., Campoccia, G., Sabatino, M., Pozzessere, D., Petrioli, R., Lozzi, L., Neri, P., Fanetti, G., Cusi, M. G., Correale, P. (2002). High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects. J. Immunol. 169: 4840-4849 [Abstract] [Full Text]
Siegel, C. T., Schreiber, K., Meredith, S. C., Beck-Engeser, G. B., Lancki, D. W., Lazarski, C. A., Fu, Y.-X., Rowley, D. A., Schreiber, H. (2000). Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein. JEM 191: 1945-1956 [Abstract] [Full Text]
Zhu, M., Marshall, J., Cole, D., Schlom, J., Tsang, K. Y. (2000). Specific Cytolytic T-Cell Responses to Human CEA from Patients Immunized with Recombinant Avipox-CEA Vaccine. Clin. Cancer Res. 6: 24-33 [Abstract] [Full Text]
Tanaka, Y., Ohyama, H., Ogawa, M., Nishimura, Y., Matsushita, S. (1999). Identification of Peptide Superagonists for a Self-K-ras-Reactive CD4+ T Cell Clone Using Combinatorial Peptide Libraries and Mass Spectrometry. J. Immunol. 162: 7155-7161 [Abstract] [Full Text]
Evans, T.R.J., Kaye, S.B. (1999). Vaccine therapy for cancer�fact or fiction?. QJM 92: 299-307 [Full Text]
Fayolle, C., Ladant, D., Karimova, G., Ullmann, A., Leclerc, C. (1999). Therapy of Murine Tumors with Recombinant Bordetella pertussis Adenylate Cyclase Carrying a Cytotoxic T Cell Epitope. J. Immunol. 162: 4157-4162 [Abstract] [Full Text]
Greten, T. F., Jaffee, E. M. (1999). Cancer Vaccines. JCO 17: 1047-1047 [Abstract] [Full Text]
Sarma, S., Guo, Y., Guilloux, Y., Lee, C., Bai, X.-F., Liu, Y. (1999). Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo. JEM 189: 811-820 [Abstract] [Full Text]
Correale, P., Walmsley, K., Zaremba, S., Zhu, M., Schlom, J., Tsang, K. Y. (1998). Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide. J. Immunol. 161: 3186-3194 [Abstract] [Full Text]
Guillaume, T., Rubinstein, D. B., Symann, M. (1998). Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation. Blood 92: 1471-1490 [Full Text]
Dubey, P., Hendrickson, R. C., Meredith, S. C., Siegel, C. T., Shabanowitz, J., Skipper, J. C.A., Engelhard, V. H., Hunt, D. F., Schreiber, H. (1997). The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68. JEM 185: 695-706 [Abstract] [Full Text]
Huang, A., Golumbek, P, Ahmadzadeh, M, Jaffee, E, Pardoll, D, Levitsky, H (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965 [Abstract]
Boon, T., Van den Eynde, B., Hirsch, H., Moroni, C., De Plaen, E., van der Bruggen, P., De Smet, C., Lurquin, C., Szikora, J.-P., De Backer, O. (1994). Genes Coding for Tumor-specific Rejection Antigens. Cold Spring Harb Symp Quant Biol 59: 617-622 [Abstract]